A new trading day began on Friday, with Protagonist Therapeutics Inc (NASDAQ: PTGX) stock price up 11.55% from the previous day of trading, before settling in for the closing price of $41.65. PTGX’s price has ranged from $16.80 to $48.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 2462.45%. Meanwhile, its annual earnings per share averaged 284.28%. With a float of $56.31 million, this company’s outstanding shares have now reached $57.71 million.
Considering the fact that the conglomerate employs 112 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 99.21%, operating margin of 46.05%, and the pretax margin is 53.45%.
Protagonist Therapeutics Inc (PTGX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Protagonist Therapeutics Inc is 5.52%, while institutional ownership is 100.40%. The most recent insider transaction that took place on Nov 15 ’24, was worth 78,108. In this transaction Chief Medical Officer of this company sold 1,906 shares at a rate of $40.98, taking the stock ownership to the 46,444 shares. Before that another transaction happened on Sep 11 ’24, when Company’s Chief Financial Officer sold 14,203 for $44.49, making the entire transaction worth $631,872. This insider now owns 34,960 shares in total.
Protagonist Therapeutics Inc (PTGX) Earnings and Forecasts
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.44 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 284.28% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
Here are Protagonist Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 10.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.54. Likewise, its price to free cash flow for the trailing twelve months is 13.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.67, a number that is poised to hit 0.31 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Compared to the last year’s volume of 0.75 million, its volume of 1.37 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 65.11%. Additionally, its Average True Range was 2.68.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 85.17%, which indicates a significant increase from 84.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.81% in the past 14 days, which was higher than the 43.88% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.25, while its 200-day Moving Average is $35.89. Nevertheless, the first resistance level for the watch stands at $48.51 in the near term. At $50.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $53.61. If the price goes on to break the first support level at $43.41, it is likely to go to the next support level at $40.35. Should the price break the second support level, the third support level stands at $38.31.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
With a market capitalization of 3.09 billion, the company has a total of 59,598K Shares Outstanding. Currently, annual sales are 60,000 K while annual income is -78,960 K. The company’s previous quarter sales were 4,680 K while its latest quarter income was -33,210 K.
